PT  - JOURNAL ARTICLE
AU  - Matthew B. Stern
TI  - Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease
AID  - 10.1212/WNL.49.1_Suppl_1.S2
DP  - 1997 Jul 01
TA  - Neurology
PG  - S2--S9
VI  - 49
IP  - 1 Suppl 1
4099  - http://n.neurology.org/content/49/1_Suppl_1/S2.short
4100  - http://n.neurology.org/content/49/1_Suppl_1/S2.full
SO  - Neurology1997 Jul 01; 49
AB  - A number of unresolved issues complicate the effective management of patients with Parkinson's disease (PD). Chief among these is the role of neuroprotective versus symptomatic pharmacologic interventions. Until the etiology of PD is further defined, consensus on appropriate management of this illness is unlikely. Clinicians may best serve their patients by taking a pragmatic approach to the treatment of PD that utilizes potentially beneficial interventions in eligible patients. Such an approach would incorporate possible neuroprotective (e.g., selegiline, dopamine agonists, sustained-release levodopa) and dopamine-sparing (e.g., combination levodopa/dopamine agonist therapy) strategies whenever possible while retaining adequate symptomatic control.